---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023715"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:42:41.219206+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Abeona reports Q2 net income of $108.8M on PRV sale; ZEVASKYN launch on track

## Summary
- Net income $108.8M ($2.07 basic EPS) vs $7.4M in Q2 2024; includes $155M gain from PRV sale.
- Cash $225.9M expected to fund operations over two years without anticipated ZEVASKYN revenue.
- First ZEVASKYN patient treatment expected in Q3 2025; multiple patients identified at QTCs.
- 100% of prior authorization requests approved; United Healthcare issued favorable coverage policy.
- R&D expense fell to $5.9M; SG&A rose to $17.1M due to commercial launch costs.

## SEC filing metadata
- accession: 0001641172-25-023715
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000164117225023715/0001641172-25-023715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000164117225023715/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023715
- JSON: https://secwatch.observer/filing/0001641172-25-023715.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023715.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.